Artelo Flags Nasdaq $5M MVLS Delisting Risk, Weighs More Dilutive Financing
ARTL is trading near its 52-week low of $3.19 (0.0% above the low) on light trading volume (0.1× avg).
Summary
Artelo disclosed it is among ~180 Nasdaq companies below the new $5M MVLS threshold, putting it at risk of delisting. The company may use its ATM or other equity financings to regain compliance, adding dilution risk for shareholders.
Key Events · Legal and Risk Events · ARTL
-
Nasdaq $5M MVLS Non-Compliance Identified
Artelo is among ~180 Nasdaq companies identified as having a market value of listed securities below the new $5 million threshold, exposing it to potential delisting proceedings.
-
Contingency Plans Include More Dilution
To regain compliance, the company may raise capital through its existing ATM program or other equity or equity-linked financings, actions with respect to outstanding warrants, or other corporate actions.
-
SEC Proposes Delaying Rule Operative Date
On October 5, 2026, the SEC published a Nasdaq proposed rule change to modify the operative date of the $5M MVLS Rule to be upon termination of the temporary stay; comments are due by October 29, 2026.
-
No Committed Course of Action
The company has not committed to any particular strategy, is not soliciting proposals, and will not disclose further developments unless required or appropriate.
Analysis · ARTL · Life Sciences
Artelo disclosed it is among roughly 180 Nasdaq companies identified as falling below the new $5 million market value of listed securities threshold, exposing it to potential delisting proceedings. With a market cap of only about $1.8 million and the stock trading at its 52-week low of $3.19, the company is already deep in non-compliance territory. The filing states that if the rule takes effect, Artelo may raise capital through its existing ATM program or other equity-linked financings — a move that would further dilute shareholders already battered by a 1-for-9 reverse split and a going-concern warning. The SEC's October 5 proposed rule change to delay the operative date until the temporary stay ends gives the company some breathing room, but the path to compliance likely requires either a substantial share-price recovery or additional dilutive issuance.
How filings like this one have moved
In the 30 days to Oct 9, 2026, 36.7% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ARTL was trading at $3.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8M. The 52-week trading range was $3.19 to $179.19. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.